Disclosures for "Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20"
-
Dr. Vukic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. Dr. Vukic has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Vukic has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Vukic has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Vukic has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for Argenx. Dr. Vukic has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for UCB. Dr. Vukic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Vukic has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for J and J.
-
Author has nothing to disclose
-
Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL Behring. Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Stino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Stino has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Stino has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Annexon. The institution of Dr. Stino has received research support from GBS-CIDP Foundation. The institution of Dr. Stino has received research support from Bristol Myers Squibb.
-
Author has nothing to disclose
-
Author has nothing to disclose